Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1481–1484.

https://doi.org/10.1182/blood-2022-160090

Published: 2022

Journal Articles

Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Blood (2022) 140 (Supplement 1): 1479–1480.

https://doi.org/10.1182/blood-2022-158981

Published: 2022

Journal Articles

Impact of Comorbidities on Outcomes of Peripheral T Cell Lymphoma in Elderly Patients: An International Retrospective Study

Monica Mead, MD BS, Henrik Cederleuf, MD, Thomas Relander, MD PhD, Mats Jerkeman, MD PhD, Fredrik Ellin, MD PhD, Daria Gaut, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-134814

Published: 2020

Journal Articles

Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials

Bettina Altmann, PhD, Gerald Wulf, MD, Lorenz Truemper, MD, Francesco d'Amore, MD, Thomas Relander, Helle Toldbod, MS,PhD, Jan M.A. Delabie, MD PhD, Andreas Rosenwald, Marita Ziepert, PhD, Markus Loeffler, MD

Blood (2018) 132 (Supplement 1): 1622.

https://doi.org/10.1182/blood-2018-99-112076

Published: 2018

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK , DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis

Blood (2017) 130 (Supplement 1): 822.

https://doi.org/10.1182/blood.V130.Suppl_1.822.822

Published: 2017

Journal Articles

Evaluation of the NCCN-IPI As a Prognostic Tool in PTCLs

Fredrik Ellin, MD MSc, Matthew J Maurer, MS, Line Srour, MD, Umar Farooq, MD, Mats Jerkeman, MD PhD, Joseph M Connors, MD, Karin E Smedby, MD PhD, Nabila Nora Bennani, MD, Stephen M Ansell, MD PhD, Graham W Slack, MD, James R. Cerhan, MD PhD, Thomas Relander, MD PhD, Andrew L Feldman, MD, Kerry J Savage, BSc, MD MSc

Blood (2017) 130 (Supplement 1): 2795.

https://doi.org/10.1182/blood.V130.Suppl_1.2795.2795

Published: 2017

Journal Articles

An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma

Matthew J Maurer, MS, Fredrik Ellin, MDPhD, Line Srour, MD, Mats Jerkeman, Nabila Nora Bennani, MD, Joseph M. Connors, Karin Ekstrom Smedby, MD PhD, Stephen Ansell, MD PhD, Brian K Link, MD, James R Cerhan, MD PhD, Thomas Relander, MD PhD, Kerry J Savage, MD, Andrew L Feldman, MD

Blood (2016) 128 (22): 920.

https://doi.org/10.1182/blood.V128.22.920.920

Published: 2016

Journal Articles

Response at Interim Evaluation Predicts Survival after Autologous Stem Cell Transplantation in Nodal Peripheral T-Cell Lymphoma; A Nordic Lymphoma Group Study

Fredrik Ellin, MD PhD, Knut Liestøl, Susanna Mannisto, Grete F Lauritzsen, MD, Esa Jantunen, MD PhD, Peter A Meyer, Helle Toldbod, Thomas Relander, MD PhD, Francesco A d'Amore, MD

Blood (2016) 128 (22): 1830.

https://doi.org/10.1182/blood.V128.22.1830.1830

Published: 2016

Journal Articles

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Michael Roost Clausen, MD, Sirpa Leppa, MD, Peter de Nully Brown, MD, Jette Soenderskov Goerloev, MD, Michael Panny, MD, Wolfgang Willenbacher, MD, Ida Blok Sillesen, MD, Erik Segel, MD, Hans Bentzen, MD, Michael Thorsgaard, MD, Elisa Jacobsen Pulczynski, MD, Peter Kamper, MD, Lars C. Gormsen, MD, Julie Mortensen, MDcal Student, Grethe Lauritzsen, MD, Thomas Relander, MD PhD, Francesco d'Amore, MD PhD

Blood (2016) 128 (22): 1782.

https://doi.org/10.1182/blood.V128.22.1782.1782

Published: 2016

Journal Articles

Valproate in Combination with Rituximab and CHOP As First Line Therapy in Diffuse Large B-Cell Lymphoma (VALFRID): Preliminary Results from a Phase I Trial with a Dose Expansion Cohort

Kristina Drott, MD PhD, Hans Hagberg, MD PhD, Thomas Relander, MD PhD, Cecilia Graffman, MD PhD, Johan Drott, PhD, Mats Jerkeman, MD PhD

Blood (2015) 126 (23): 3939.

https://doi.org/10.1182/blood.V126.23.3939.3939

Published: 2015

Journal Articles

Addition of Etoposide to CHOP Is Associated with Improved Outcome in Adult Anaplastic Large Cell Lymphoma Patients: A Nordic Lymphoma Group Study

Henrik Cederleuf, MD, Martin BjerregÃ¥rd Pedersen, MD PhD, Mats Jerkeman, MD PhD, Thomas Relander, MD PhD, Francesco d'Amore, MD, Fredrik Ellin, MD MSc

Blood (2015) 126 (23): 340.

https://doi.org/10.1182/blood.V126.23.340.340

Published: 2015

Journal Articles

Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma

Matthew J Maurer, MS, Fredrik Ellin, MD MSc, James Cerhan, MD PhD, Stephen Ansell, MD PhD, Brian K Link, MD, Mats Jerkeman, MD PhD, Karin E Smedby, MD PhD, Carrie A. Thompson, MD, William Macon, MD, Sergei Syrbu, MD, Susan L. Slager, PhD, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Thomas Relander, MD PhD, Andrew L Feldman, MD

Blood (2015) 126 (23): 1501.

https://doi.org/10.1182/blood.V126.23.1501.1501

Published: 2015

Journal Articles

Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study

Fredrik Ellin, Jenny Landström, Mats Jerkeman, Thomas Relander

Blood (2015) 126 (1): 36–41.

https://doi.org/10.1182/blood-2014-12-616961

Published: 2015

Journal Articles

Patterns of Central Nervous System Relapse in Peripheral T-Cell Lymphomas – Population-Based Data from the Swedish Lymphoma Registry

Fredrik Ellin, MD, Jenny Landström, Mats Jerkeman, MD PhD, Thomas Relander

Blood (2014) 124 (21): 1632.

https://doi.org/10.1182/blood.V124.21.1632.1632

Published: 2014

Journal Articles

The Prognostic Impact of Comorbidity in Peripheral T-Cell Lymphomas: a Swedish Lymphoma Registry Study

Fredrik Ellin, MD, Jenny Landström, Mats Jerkeman, MD PhD, Thomas Relander

Blood (2014) 124 (21): 1635.

https://doi.org/10.1182/blood.V124.21.1635.1635

Published: 2014

Journal Articles

Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry

Fredrik Ellin, Jenny Landström, Mats Jerkeman, Thomas Relander

Blood (2014) 124 (10): 1570–1577.

https://doi.org/10.1182/blood-2014-04-573089

Published: 2014

Includes: Supplemental data

Journal Articles

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Blood (2012) 120 (21): 57.

https://doi.org/10.1182/blood.V120.21.57.57

Published: 2012

Journal Articles

Treatment Outcome in T-Cell Lymphoblastic Lymphoma in Adults - a Population-Based Study From the Swedish Lymphoma Registry.

Fredrik Ellin, MD, Mats Jerkeman, Thomas Relander

Blood (2012) 120 (21): 2727.

https://doi.org/10.1182/blood.V120.21.2727.2727

Published: 2012

Journal Articles

High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)

Blood (2011) 118 (21): 331.

https://doi.org/10.1182/blood.V118.21.331.331

Published: 2011

NARROW

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Impact of Comorbidities on Outcomes of Peripheral T Cell Lymphoma in Elderly Patients: An International Retrospective Study

Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK , DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis

Evaluation of the NCCN-IPI As a Prognostic Tool in PTCLs

An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma

Response at Interim Evaluation Predicts Survival after Autologous Stem Cell Transplantation in Nodal Peripheral T-Cell Lymphoma; A Nordic Lymphoma Group Study

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Valproate in Combination with Rituximab and CHOP As First Line Therapy in Diffuse Large B-Cell Lymphoma (VALFRID): Preliminary Results from a Phase I Trial with a Dose Expansion Cohort

Addition of Etoposide to CHOP Is Associated with Improved Outcome in Adult Anaplastic Large Cell Lymphoma Patients: A Nordic Lymphoma Group Study

Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma

Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study

Patterns of Central Nervous System Relapse in Peripheral T-Cell Lymphomas – Population-Based Data from the Swedish Lymphoma Registry

The Prognostic Impact of Comorbidity in Peripheral T-Cell Lymphomas: a Swedish Lymphoma Registry Study

Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Treatment Outcome in T-Cell Lymphoblastic Lymphoma in Adults - a Population-Based Study From the Swedish Lymphoma Registry.

High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only